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Psoriatic arthritis
AbstrAct
Objectives to determine the proportion of patients with 
psoriatic arthritis in the adalimumab effectiveness in 
Psoriatic arthritis trial achieving minimal disease activity 
(MDa) and its individual components at 1 or more visits 
over 144 weeks, identify baseline predictors of MDa 
achievement, and evaluate the association of MDa status 
with independent quality of life (Qol)-related patient-
reported outcomes (PrOs).
Methods Univariate and multivariate analyses were used 
to identify the baseline characteristics that predicted 
achievement of MDa at individual time points (weeks 12 
through 144) or sustained MDa (achievement of MDa at 2 
consecutive time points 12 weeks apart). the association 
of independent Qol-related PrOs with MDa achievement 
was evaluated at weeks 24 and 144.
Results in univariate analyses, higher baseline patient 
assessment of pain, tender joint count (tJc), enthesitis and 
Health assessment Questionnaire-Disability index (HaQ-Di) 
score were significantly associated with lower likelihood 
of achieving MDa at later time points. Multivariate 
analyses confirmed higher baseline HaQ-Di as a significant 
predictor for failure to achieve MDa at later time points. 
achievement of sustained MDa was associated with lower 
baseline tJc and HaQ-Di score. achievement of different 
MDa components appeared to be treatment dependent. 
MDa achievers had significantly better Qol-related PrOs 
and greater improvements in PrOs from baseline to week 
24 compared with non-achievers.
Conclusions Higher HaQ-Di score was the most 
consistent baseline factor that decreased the likelihood 
of achieving MDa and sustained MDa at later time points. 
achieving MDa was associated with better independent 
Qol-related PrOs.
IntroductIon
Psoriatic arthritis (PsA) is a chronic systemic 
inflammatory disease that affects the 
synovium, tendons, entheses and bone, and 
is associated with varied tissue pathology.1 2 
PsA is thus characterised clinically by arthritis, 
enthesitis and dactylitis in addition to skin 
and nail psoriasis.3 4 Approximately 30% of 
patients with psoriasis develop PsA.2 Joint 
damage and functional impairment may 
result from uncontrolled disease.1 The Euro-
pean League Against Rheumatism, Group 
for Research and Assessment of Psoriasis 
and Psoriatic Arthritis, and a PsA treat-to-
target task force recommend remission or 
low/minimal disease activity (MDA) as treat-
ment targets for patients with PsA.5–7 The 
criteria for MDA in PsA were developed8 
and validated as a clinically meaningful and 
comprehensive treatment target for PsA,9 10 
which encompasses skin, joints and entheses. 
MDA corresponds to a state of low disease 
Key messages
What is already known about this subject?
 ► there is limited understanding of patient and disease 
characteristics that predict long-term minimal 
disease activity  (MDa) achievement and potential 
benefits associated with achievement of MDa.
What does this study add?
 ► the present study provides further insights into the 
achievement, prediction and benefits of MDa status 
in patients treated with adalimumab.
 ► it further confirms higher baseline Health 
assessment Questionnaire-Disability index as a 
significant negative predictor for MDa achievement.
 ► MDa achievement was associated with significantly 
better quality of life-related patient-reported 
outcomes (PrOs) and greater improvements in PrOs 
from baseline.
How might this impact on clinical practice?
 ► Our data provide further support for MDa as a 
valid treatment target in psoriatic arthritis, since its 
achievement is associated with meaningful benefits 
in PrOs other than those included in the MDa 
calculation.
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activity or remission in PsA,9 11 and patients who achieve 
MDA have less radiographic progression and functional 
impairment than patients who fail to reach this target.10 12
In the Adalimumab Effectiveness in Psoriatic Arthritis 
(ADEPT13) trial, a significantly higher number of patients 
treated with adalimumab achieved MDA compared 
with those treated with placebo at week 24 (39% vs 7%, 
respectively).14 However, the attainment of individual 
MDA components in MDA achievers has not been exten-
sively evaluated.15 Identification of MDA components 
that are difficult to achieve may ascertain clinical or 
pathological factors that merit future attention in disease 
management strategies. Additionally, there is limited 
understanding of patient and disease characteristics that 
predict MDA achievement over longer term and of other 
potential benefits associated with achievement of MDA.16 
The aim of the present analysis was to determine which 
baseline clinical and/or patient demographic character-
istics predict the achievement of MDA over 144 weeks in 
patients with PsA included in the ADEPT trial and to eval-
uate the achievement of individual MDA components, 
as well as the association of MDA status with indepen-
dent quality of life (QoL)-related patient-reported 
outcomes (PROs) (not included in MDA criteria).
Methods
Patients and study
The methods and primary results of the phase 3, double-
blind, placebo-controlled ADEPT trial (NCT00646386) 
of adalimumab in patients with moderately to severely 
active PsA are published.13 Briefly, ADEPT patients 
were ≥18 years of age, had active PsA (≥3 tender 
and ≥3 swollen joints) and an inadequate response or 
intolerance to non-steroidal anti-inflammatory drugs. 
Patients were randomised 1:1 to receive adalimumab 
40 mg or placebo every other week for 24 weeks, after 
which they were eligible to enter an extension study in 
which they received open-label adalimumab for up to 144 
weeks. The present analysis included a subset of ADEPT 
patients randomised to adalimumab (n=66) and placebo 
(n=69) who had active skin disease at baseline (body 
surface area ≥3%) and in whom MDA could be calcu-
lated (at least 5/7 MDA components available).
Minimal disease activity
MDA was defined as achieving ≥5 of the following 
seven criteria8: tender joint count of 78 joints (TJC) ≤1; 
swollen joint count of 76 joints (SJC) ≤1; Psoriasis Area 
and Severity Index (PASI) ≤1; patient assessment of 
pain (patient pain) ≤15 on a 0–100 mm visual analogue 
scale (VAS); Patient Global Assessment of disease activity 
(PtGA) ≤20 on a 0–100 mm VAS; Health Assessment Ques-
tionnaire-Disability Index (HAQ-DI) ≤0.5; and tender 
entheseal points (assessed bilaterally at two sites) ≤1. 
Patients who met MDA criteria were termed ‘achievers’ 
and those who did not were termed ‘non-achievers.’ 
Sustained MDA was defined as MDA achievement at two 
consecutive time points 12 weeks apart, except for week 
144, where the previous visit was 16 weeks earlier.
Baseline variables tested as predictors of MDA included 
age (years), sex, weight (kg), duration of psoriasis or PsA 
since diagnosis (years), structural damage measured by 
modified total Sharp score, TJC, SJC, PASI (range, 0–72), 
C-reactive protein (mg/dL), patient pain, PtGA, HAQ-DI, 
enthesitis (absent vs present at two bilateral sites (prox-
imal insertion of Achilles tendon, insertion of plantar 
fascia)), Physician Global Assessment of disease activity 
(PhGA, 0–100 mm VAS) and Physician Global Assess-
ment of psoriasis (PhGA-P) on a 7-point scale ranging 
from severe (very marked plaque elevation, scaling and/
or erythema) to clear (no sign of psoriasis).
Patient-reported outcomes
Health-related QoL was assessed using the Short Form 
36 (SF-36) Health Survey questionnaire (total score, 
physical component summary score (PCS) and mental 
component summary score (MCS)) and Dermatology 
Life Quality Index (DLQI). Fatigue was assessed using 
the Functional Assessment of Chronic Illness Therapy-Fa-
tigue (FACIT-F) score.
statistical analysis
The percentage of patients achieving MDA over time 
was assessed using observed data and non-responder 
imputation. Baseline characteristics that predicted the 
achievement of MDA or sustained MDA at weeks 12, 
24, 48, 96 and 144 were identified using univariate and 
multivariate analyses. For multivariate analyses, the least 
absolute shrinkage and selection operator method was 
used to refine baseline variable selection. Penalties were 
added to constrain regression coefficients in the presence 
of correlated data. The positive predictive value (PPV) or 
negative predictive value (NPV) of week 12 MDA status to 
determine MDA status at week 24 or 144 was determined 
using a two-way contingency table. Analyses of PROs at 
week 24 (and for completers at week 144) were based on 
observed data, with each analysis conducted on the avail-
able data at a particular time point.
results
Achievement of MDA and sustained MDA through week 144
At the end of the 24-week double-blind period, 36.4% 
(24/66) of patients randomised to receive adalimumab 
achieved MDA compared with 5.8% (4/69) receiving 
placebo while sustained MDA was achieved by 34.8% 
(23/66) and 5.8% (4/69) of patients receiving adali-
mumab and placebo, respectively. At week 24, very 
low disease activity, defined as achieving MDA score of 
7/7, was attained by 15.4% (10/65) and 0% (0/61) of 
patients treated with adalimumab and placebo, respec-
tively. During the open-label period, MDA rate was either 
maintained or higher in patients initially randomised to 
adalimumab whereas MDA rate was numerically lower 
throughout the follow-up in patients switching to open-
label adalimumab after receiving placebo for 24 weeks 
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(figure 1). Similarly, throughout the open-label period, 
the rate of sustained MDA was higher among patients 
initially randomised to adalimumab compared with 
placebo: week 48, 43.1% (25/58) vs 32.2% (19/59); week 
96, 37.9% (22/58) vs 27.1% (16/59); and week 144, 
34.5% (20/58) vs 22.0% (13/59). Of the 88 patients who 
completed the 144-week open-label period, 15 (17.1%) 
achieved MDA at every time point from week 24 through 
week 144.
univariate analysis of factors associated with achievement 
of long-term and sustained MdA
In the univariate analysis, higher scores at baseline for 
TJC, patient pain and HAQ-DI were significantly asso-
ciated with lower odds of achieving MDA at every time 
point. Higher SJC and higher enthesitis scores or pres-
ence of enthesitis at baseline were associated with lower 
odds of achieving MDA at most time points (figure 2). At 
every time point, lower baseline TJC, SJC and HAQ-DI 
scores were associated with higher odds of achieving 
sustained MDA (data not shown).
Multivariate analysis of factors associated with 
achievement of long-term and sustained MdA
Multivariate analysis confirmed higher baseline HAQ-DI 
score as a significant predictor for failure to achieve MDA 
at later time points (figure 3). A 1-unit increase in base-
line HAQ-DI reduced the odds of achieving MDA at later 
time points by 64%–77%. Lower age, TJC and HAQ-DI 
at baseline were associated with sustained MDA at week 
48, and lower enthesitis at baseline was associated with 
sustained MDA at week 144 (online supplementary figure 
1).
Prediction of MdA at later time points based on MdA status 
at week 12
MDA status at week 12 had a 100% PPV, 95.7% NPV, 
100% specificity and 85.2% sensitivity for predicting 
MDA status at week 24. MDA status at week 12 had 100% 
PPV, 64.7% NPV, 100% specificity and 40.0% sensitivity 
for predicting MDA status at week 144. The high NPV 
(95.7%) for prediction of week 24 MDA status indi-
cated a good ability of week-12 MDA non-achievement 
to predict MDA non-achievement at week 24. However, 
the moderate NPV (64.7%) for prediction of week-144 
MDA status indicated a poor ability of week-12 MDA 
non-achievement to predict MDA non-achievement at 
week 144.
Achievement of individual MdA components
The comparison of individual MDA components at base-
line between MDA achievers and non-achievers at week 
24 is presented in online supplementary table 1. MDA 
achievers, especially those receiving placebo, trended 
towards lower mean scores for the individual MDA 
components at baseline.
At week 24, in adalimumab-treated patients regard-
less of their MDA status, SJC≤1 (MDA achievers, 58.3% 
(14/24); MDA non-achievers, 13.5% (5/37)) and TJC≤1 
(MDA achievers, 83.3% (20/24); MDA non-achievers, 
10.8% (4/37)) were achieved by the smallest number 
of patients; whereas in patients treated with placebo, 
PASI was achieved by the lowest number of patients 
(MDA achievers, 0% (0/4); MDA non-achievers, 3.6% 
(2/55), table 1). Although a high proportion of MDA 
achievers and non-achievers satisfied the enthesitis 
Figure 1 Achievement of MDA over 144 weeks in patients initially receiving adalimumab or placebo during the double-blind 
period. Data are presented as observed (solid lines) and using NRI (dashed lines). Patients who escalated to weekly dosing 
on or after week 36 were counted as non-responders. Numbers of patients at each study visit are presented below the graph. 
ADA, adalimumab; MDA, minimal disease activity; NRI, non-responder imputation; OBS, as observed; PBO, placebo.
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criterion throughout the study, fewer than half of the 
patients (adalimumab, 41.7% (25/60); placebo, 39.0% 
(23/59)) had baseline entheseal involvement in ≥1 of 
the two enthesial sites assessed. The differences between 
the rates of achieving individual MDA components 
were less pronounced during the open-label period 
(online supplementary file 3). At week 144, in patients 
initially treated with placebo, patient pain ≤15 and TJC≤1 
were the two MDA components that were consistently met 
by the lowest number of patients and could therefore be 
considered the limiting components for achieving MDA 
after delayed adalimumab introduction (online supple-
mentary file 3).
To evaluate the contribution of each individual MDA 
component to MDA achievement at the group level, indi-
vidual MDA components were omitted separately from 
the MDA calculation (MDA 5/6, defined as achievement 
of ≥5 of 6 criteria). Exclusion of SJC did not impact the 
MDA 5/6 rate at week 24 in patients treated with adalim-
umab, whereas exclusion of TJC or PASI decreased MDA 
Figure 2 OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. CRP, 
C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; mTSS, modified 
total Sharp score; PASI, Psoriasis Area and Severity Index; PhGA, Physician Global Assessment of disease activity; PhGA-P, 
Physician Global Assessment of psoriasis; Ps, psoriasis; PsA, psoriatic arthritis; PtGA, Patient Global Assessment of disease 
activity; SJC, swollen joint count of 76 joints; TJC, tender joint count of 78 joints. *Statistically significant predictor of MDA.
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achievement by 3.2%; exclusion of patient pain, PtGA, 
HAQ-DI or enthesitis decreased MDA achievement by 
6.5%. This suggested a relatively equal contribution of 
individual MDA components to achieving MDA at the 
population level.
relationship between disease duration and hAQ-dI
We next explored the relationship between HAQ-DI, 
a negative predictor of MDA achievement, and disease 
duration. Generally, HAQ-DI increased with longer PsA 
duration both at baseline as well as at various study time 
points (figure 4), but the correlation between PsA dura-
tion and HAQ-DI was weak (correlation coefficient <0.3). 
The mean HAQ-DI score exceeded 0.5 at weeks 96 and 
144 in patients with PsA duration of >8 years (figure 4), 
suggesting that in a substantial proportion of patients 
with long-standing PsA, the impairment in physical 
function related to irreversible damage could prevent 
achievement of this MDA criterion even with effective 
control of inflammation.
Qol-related Pros associated with MdA achievement
At week 24, independent QoL-related PROs (those not 
included in the MDA criteria) were significantly better in 
MDA achievers than MDA non-achievers (figure 5A,B), 
including higher mean SF-36 total (p<0.001), PCS 
(p<0.001) and MCS (p<0.01) scores, higher FACIT-F 
score (p<0.001) and lower DLQI score (p<0.001). MDA 
achievers at week 24 had favourable mean (±SD) PRO 
scores at baseline compared with MDA non-achievers 
for SF-36 total (58.0±19.0 vs 46.5±19.7; p<0.01) and 
PCS (37.7±12.0 vs 31.6±9.1; p<0.01) scores, as well as 
FACIT-F (34.9±10.9 vs 29.2±12.2; p<0.05) scores, but 
not SF-36 MCS (48.2±11.0 vs 45.6±12.1; p=0.314) and 
DLQI (7.9±5.6 vs 9.7±7.4; p=0.243) scores. Age, sex, 
PsA duration and methotrexate use did not influence 
Figure 3 OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed 
data. Statistically significant variables in the univariate analysis were further selected with LASSO to adjust for confounding 
factors and collinearity. HAQ-DI, Health Assessment Questionnaire-Disability Index; LASSO, least absolute shrinkage and 
selection operator method; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; Ps, psoriasis; SJC, swollen 
joint count of 76 joints; TJC, tender joint count of 78 joints. *Statistically significant predictor of MDA.
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results for SF-36, FACIT-F or DLQI in MDA achievers 
versus MDA non-achievers (data not shown).
Furthermore, MDA achievers experienced larger mean 
changes from baseline for the evaluated PROs than MDA 
non-achievers (figure 5C,D); these changes reached 
the established minimal clinically important difference 
(MCID) for all the evaluated PROs.17 Although the mean 
change from baseline in SF-36 total and PCS scores for 
MDA non-achievers reached the MCID, these changes 
were of a lower magnitude compared with MDA achievers. 
For patients who completed 144 weeks, no significant 
differences in PRO scores were observed between MDA 
achievers and non-achievers at the end of follow-up (data 
not shown).
dIscussIon
MDA has been established as a validated composite 
outcome measure in PsA that is discriminative and has 
prognostic value in terms of structural damage. Further, 
its use as a treatment target in the first treat-to-target trial 
in PsA (TIght COntrol of Psoriatic Arthritis; TICOPA) 
resulted in improved joint, skin and PROs compared 
with standard care following no treatment target.18 19 
With the trend for increased use of MDA as a clinical trial 
endpoint, as well as its adoption into clinical practice,5 6 it 
is important to fully understand predictors of MDA and 
the contribution of individual MDA components to the 
overall MDA achievement, as well as potential associa-
tions of MDA status with other outcomes. The current 
analysis provided insights into the achievement, predic-
tion and benefits of MDA that were obtained within the 
randomised, placebo-controlled ADEPT trial of adalim-
umab, including its open-label extension through week 
144.
Nearly 40% of patients treated with adalimumab were 
previously reported to have achieved MDA by the end 
of the 24-week, double-blind period of ADEPT.14 The 
present analysis showed that the proportion of patients 
Table 1 Attainment of individual MDA components in MDA achievers and non-achievers at week 24 by randomised 
treatment
MDA component
MDA achievers MDA non-achievers
Patients meeting 
criterion, n (%)
Response difference
(95% CI)
Patients meeting 
criterion, n (%)
Response difference
(95% CI)
Adalimumab
(n=24)
Placebo
(n=4)
Adalimumab 
(n=37)
Placebo
(n=55)
TJC≤1 20 (83.3) 3 (75.0) 8.3 (–36.6 to 53.3) 4 (10.8) 3 (5.5) 5.4 (–6.3 to 17.0)
SJC≤1 14 (58.3) 2 (50.0) 8.3 (–44.9 to 61.2) 5 (13.5) 6 (10.9) 2.6 (–11.2 to 16.4)
PASI≤1 21 (87.5) 0 87.5 (74.3 to 100)* 15 (40.5) 2 (3.6) 36.9 (20.3 to 53.5)**
Patient pain ≤15 24 (100) 4 (100) 0 6 (16.2) 3 (5.5) 10.8 (–2.6 to 24.1)
PtGA≤20 24 (100) 4 (100) 0 6 (16.2) 7 (12.7) 3.5 (–11.3 to 18.3)
HAQ-DI≤0.5 23 (95.8) 4 (100) –4.2 (–12.2 to 3.8) 8 (21.6) 17 (30.9) –9.3 (–27.3 to 8.7)
Tender entheseal 
points ≤1
24 (100) 4 (100) 0 26 (70.3) 35 (63.6) 6.6 (–12.8 to 26.1)
**p<0.001; *p<0.01.
 HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PtGA, 
Patient Global Assessment of disease activity; SJC, swollen joint count of 76 joints; TJC, tender joint count of 78 joints. 
Figure 4 Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. The horizontal 
lines indicate the median, boxes mark the interval between the 25th and 75th percentiles, vertical lines indicate the maximum 
and minimum values, and + represents the mean. The dashed line represents HAQ-DI=0.5, which is the cut-off point for the 
MDA component. HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; PsA, psoriatic 
arthritis.
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with MDA was maintained or increased through the end 
of the 144-week open-label extension period, reaching 
up to 50% in patients initially treated with adalimumab. 
This observed MDA rate is consistent with findings in 
the open-label extension of a randomised controlled 
trial with golimumab12 and observational studies with 
antitumour necrosis factors (TNFs) in clinical practice 
settings.9 16 20 21 A fairly consistent proportion of patients 
(37%–40%) had sustained MDA, which was also in 
accordance with previous data.9 12 This adds to the body 
of evidence that long-term sustained MDA is achiev-
able with anti-TNF therapy in up to 50% of patients 
with established PsA.9 12 16 20 In a recent study, <20% 
of patients treated with methotrexate achieved MDA 
at 6 months, providing further evidence in support of 
early introduction of anti-TNF therapy.22 At week 24, 
15.4% of patients treated with adalimumab achieved an 
MDA score of 7/7, which was recently proposed as very 
low disease activity.23 This MDA 7/7 rate is consistent 
with the rates reported in patients receiving anti-TNF 
therapy.24
Patients initially randomised to placebo arm were slow 
to attain MDA following treatment with open-label adali-
mumab. Interestingly, the MDA rate among patients 
initially treated with placebo remained consistently lower 
compared with patients who initially received adalim-
umab through 144 weeks. Although the differences 
did not reach statistical significance at any time point, 
Figure 5 Mean  of SF-36 and FACIT-F (A) and DLQI (B) scores at week 24 and mean change from baseline to week 24 in SF-
36 and FACIT-F (C)  and DLQI (D) scores in MDA achievers and MDA non-achievers. Data are presented as observed. Dashed 
lines represent MCID. *p<0.01; **p<0.01; ***p<0.001. DLQI, Dermatology Life Quality Index; FACIT-F, Functional Assessment of 
Chronic Illness Therapy-Fatigue; MCID, minimal clinically important difference; MCS, mental component score; MDA, minimal 
disease activity; PCS, physical component score; SF-36, Short Form 36 Health Survey.
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this may indicate that delay in introduction of effective 
therapy could negatively impact MDA achievement, even 
in patients with long-standing PsA.
Higher scores at baseline for TJC, SJC, patient pain, 
enthesitis and HAQ-DI were significantly associated 
with lower odds of achieving MDA at most time points, 
including sustained MDA, by univariate analysis. Multi-
variate analysis confirmed high baseline HAQ-DI score as 
the most consistent predictor for failure to achieve MDA. 
A 1-unit increase in baseline HAQ-DI reduced the odds of 
achieving MDA at later time points by 64%–77%. Consis-
tent with our results, worse physical function (measured 
by HAQ-DI) was most commonly identified as a negative 
predictor of MDA in prior studies,9 12 16 21 25 whereas other 
predictive factors varied across studies.9 12 16 20 21 25 26 In 
patients with longer disease duration, the mean HAQ-DI 
scores remained high even after long-term adalimumab 
treatment. This suggests that in patients with effective 
control of inflammation, higher HAQ-DI was most likely 
due to irreversible structural damage. Previous studies 
have shown that the onset of disease symptoms of less 
than 6 or 12 months prior to starting treatment is asso-
ciated with better long-term function outcomes.27 28 This 
analysis, where higher baseline HAQ-DI scores were 
observed in established disease and associated with lower 
MDA achievement, further supports the need for early 
and effective treatment in PsA.
In patients who achieved MDA at week 24, the base-
line scores for individual MDA components were lower, 
suggesting that patients with milder disease achieve MDA 
more easily. Achieving MDA early (at week 12) was a 
strong predictor of MDA response at weeks 24 and 144. 
Although not achieving MDA early remained a good 
predictor of non-MDA status at week 24, the ability of 
week-12 MDA non-response to predict non-response at 
week 144 was relatively poor. Therefore, not achieving 
MDA at week 12 should not result in an immediate 
change to another therapy.
The joint responses (TJC and SJC criteria) appeared 
to limit MDA achievement in patients treated with adali-
mumab at the end of the double-blind period, whereas 
fewer differences in the attainment of individual MDA 
components were observed during prolonged adali-
mumab therapy. This could indicate more equivalent 
long-term adalimumab effectiveness across different 
MDA components, but could also be biased by the 
observed analysis in the open-label period. By contrast, 
patients treated with placebo had difficulty meeting the 
PASI criterion, which was not fulfilled by any of the MDA 
achievers and also not met by the highest percentage of 
MDA non-achievers at week 24. These findings suggest 
that fulfilment of individual MDA components may be 
treatment dependent. A previous study reported a highly 
active skin component still present in patients otherwise 
meeting MDA criteria; however, details of PsA therapy 
were not presented.15
Patients who achieved MDA at week 24 had signifi-
cantly better PROs reflecting improved QoL and fatigue. 
Furthermore, the MDA achievers experienced larger 
improvements from baseline than non-achievers in 
all PROs measured. The mean change from baseline 
reached MCID for all PROs in MDA achievers but not 
MDA non-achievers. Previous studies demonstrated 
lower radiographic progression and improvements in 
PROs which were included in the MDA criteria in MDA 
achievers compared with non-achievers.6 8 Our data 
provide further support for MDA as a valid treatment 
target in PsA that is associated with meaningful benefits 
as measured by PROs beyond those included in the MDA 
calculation.
The limitations of our analyses include the low patient 
numbers and the fact that ADEPT was not specifi-
cally designed to assess MDA achievement a priori. 
However, these limitations exist for most other studies of 
MDA9 12 16 20 21 25 26 and, along with different patient popu-
lations and treatments, may explain inconsistent findings 
on MDA predictors other than HAQ-DI. A recent study 
reported that patients with PsA and with fibromy-
algia had lower likelihood of achieving MDA.29 Given 
that fibromyalgia was not an exclusion criterion in the 
ADEPT study and systematic assessment for fibromyalgia 
was not performed, the impact of comorbid fibromyalgia 
cannot be assessed. Strengths of our post hoc analyses 
include a 24-week placebo-controlled period, enabling a 
comparison that is lacking in observational studies, and 
the relatively long open-label extension period with adali-
mumab treatment.
In summary, the present study provides further insights 
into the long-term achievement of MDA in patients 
treated with adalimumab and confirms higher baseline 
HAQ-DI as a negative predictor for the achievement 
of MDA, supporting the necessity for early and effec-
tive treatment in PsA before irreversible functional 
impairment occurs. Finally, it demonstrates that improve-
ments in QoL-related PROs are associated with MDA 
achievement, which lends further support to MDA as a 
meaningful treatment target in PsA.
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